Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Pharmacokinetic study
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

CHLOROQUINE

Medical condition to be studied

Coronavirus infection
Population studied

Age groups

Preterm newborn infants (0 – 27 days)
Term newborn infants (0 – 27 days)
Infants and toddlers (28 days – 23 months)
Children (2 to < 12 years)
Adolescents (12 to < 18 years)

Estimated number of subjects

100
Study design details

Main study objective

The main study parameters are 1) Description of the clinical features and risk factors of COVID-19 in hospitalized and outpatient pediatric patients in the Netherlands. 2) Description of the clinical course of COVID-19 in hospitalized and outpatient pediatric patients. 3) Description of the response to treatment, including supportive care.

Outcomes

Description of the clinical features of the COVID-19 in hospitalized and outpatient pediatric patients in the Netherlands.Description of the clinical course of the COVID-19 in hospitalized and outpatient pediatric patients.Description of the response to treatment, including supportive care. Characterization of the host responses (inflammatory parameters) to infection and COVID-19 in pediatric patients.Determine cytokine levels (e.g. IL-6) and medication concentrations (e.g. chloroquine) in scarce material.

Data analysis plan

For real-time reporting of anonymous data on the website R will be used (R Foundation for Statistical Computing, Vienna, Austria). IBM SPSS Statistics software (SPSS Statistics for Windows, IBM, Armonk, NY) will be used.Demographic and clinical characteristics will be described using standard statistical analysis methods. The descriptive data will be presented as percentages and medians ± interquartile range, or numbers with percentages.